Bluestein R H & Company Has Boosted Celgene (CELG) Position By $11.96 Million; Tekla Capital Management Has Lifted By $1.13 Million Its Ultragenyx Pharmaceutical (RARE) Position

February 23, 2018 - By Hazel Jackson

Bluestein R H & Company increased Celgene Corp (CELG) stake by 2748.6% reported in 2017Q3 SEC filing. Bluestein R H & Company acquired 82,458 shares as Celgene Corp (CELG)’s stock declined 3.49%. The Bluestein R H & Company holds 85,458 shares with $12.46M value, up from 3,000 last quarter. Celgene Corp now has $70.98 billion valuation. The stock increased 0.63% or $0.59 during the last trading session, reaching $94.37. About 1.15 million shares traded. Celgene Corporation (NASDAQ:CELG) has risen 17.00% since February 23, 2017 and is uptrending. It has outperformed by 0.30% the S&P500.

Tekla Capital Management Llc increased Ultragenyx Pharmaceutical Inc. (RARE) stake by 16.69% reported in 2017Q3 SEC filing. Tekla Capital Management Llc acquired 21,250 shares as Ultragenyx Pharmaceutical Inc. (RARE)’s stock declined 25.28%. The Tekla Capital Management Llc holds 148,558 shares with $7.91M value, up from 127,308 last quarter. Ultragenyx Pharmaceutical Inc. now has $2.34B valuation. The stock decreased 1.18% or $0.56 during the last trading session, reaching $47.09. About 198,732 shares traded. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has declined 6.49% since February 23, 2017 and is downtrending. It has underperformed by 23.19% the S&P500.

Since September 5, 2017, it had 1 buy, and 4 sales for $4.31 million activity. Another trade for 9,250 shares valued at $1.29M was made by CASEY MICHAEL D on Tuesday, September 5. 18,500 Celgene Corporation (NASDAQ:CELG) shares with value of $1.77 million were sold by KAPLAN GILLA. Another trade for 1,727 shares valued at $248,498 was made by Curran Terrie on Monday, September 25. 3,260 Celgene Corporation (NASDAQ:CELG) shares with value of $299,594 were bought by Alles Mark J.

Among 33 analysts covering Celgene Corporation (NASDAQ:CELG), 19 have Buy rating, 2 Sell and 12 Hold. Therefore 58% are positive. Celgene Corporation had 132 analyst reports since July 21, 2015 according to SRatingsIntel. The stock has “Outperform” rating by Wells Fargo on Friday, December 4. As per Friday, October 27, the company rating was maintained by Citigroup. Leerink Swann upgraded Celgene Corporation (NASDAQ:CELG) on Friday, June 16 to “Outperform” rating. Guggenheim maintained the shares of CELG in report on Thursday, December 21 with “Buy” rating. On Monday, October 23 the stock rating was maintained by Morgan Stanley with “Underweight”. Robert W. Baird downgraded Celgene Corporation (NASDAQ:CELG) on Friday, October 20 to “Neutral” rating. The firm has “Buy” rating given on Friday, August 4 by Cowen & Co. The stock of Celgene Corporation (NASDAQ:CELG) earned “Buy” rating by SunTrust on Friday, December 22. The firm has “Buy” rating by UBS given on Friday, July 24. The rating was maintained by BMO Capital Markets on Thursday, October 5 with “Buy”.

Bluestein R H & Company decreased Alibaba Grp Hldgs Sp Adr (NYSE:BABA) stake by 9,850 shares to 13,200 valued at $2.28M in 2017Q3. It also reduced Facebook Inc Cl A (NASDAQ:FB) stake by 19,833 shares and now owns 353,675 shares. Kraft Heinz Co was reduced too.

Investors sentiment decreased to 1.17 in Q3 2017. Its down 0.17, from 1.34 in 2017Q2. It is negative, as 44 investors sold CELG shares while 457 reduced holdings. 133 funds opened positions while 451 raised stakes. 603.99 million shares or 0.25% more from 602.51 million shares in 2017Q2 were reported. Moreover, Ashford Management has 0.14% invested in Celgene Corporation (NASDAQ:CELG) for 5,767 shares. Cohen Klingenstein Lc holds 0.29% or 13,240 shares. Guardian Life Insur Of America invested 0.04% of its portfolio in Celgene Corporation (NASDAQ:CELG). Hilltop Incorporated reported 4,798 shares. Conning accumulated 0.1% or 20,754 shares. Gideon holds 2,948 shares. California-based Miracle Mile Advsrs Limited Liability Company has invested 0.04% in Celgene Corporation (NASDAQ:CELG). Nbt National Bank N A New York invested 0.47% in Celgene Corporation (NASDAQ:CELG). Utd Cap Fin Advisers Ltd invested in 198,808 shares. Prudential Public Limited Company holds 261,889 shares. 60,403 were reported by Busey. Strategic Advisors reported 0.4% stake. Moreover, Montag And Caldwell Limited Liability Co has 3.34% invested in Celgene Corporation (NASDAQ:CELG). Parallax Volatility Advisers LP accumulated 47,795 shares. Muhlenkamp & accumulated 71,455 shares or 3.28% of the stock.

Tekla Capital Management Llc decreased Global Blood Therapeutics Inc. stake by 62,500 shares to 62,500 valued at $1.94 million in 2017Q3. It also reduced Amgen Inc. (NASDAQ:AMGN) stake by 64,550 shares and now owns 620,274 shares. Exelixis Inc. (NASDAQ:EXEL) was reduced too.

Investors sentiment decreased to 1.19 in 2017 Q3. Its down 0.65, from 1.84 in 2017Q2. It worsened, as 17 investors sold RARE shares while 40 reduced holdings. 15 funds opened positions while 53 raised stakes. 39.75 million shares or 1.85% less from 40.50 million shares in 2017Q2 were reported. 8,550 are owned by Smith Asset Management Grp Lp. Canada Pension Plan Investment Board stated it has 6,200 shares. Nationwide Fund Advsr holds 57,314 shares or 0.01% of its portfolio. Rhumbline Advisers stated it has 46,293 shares or 0.01% of all its holdings. Invesco Limited has invested 0.01% in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). Rock Springs Cap Mngmt Ltd Partnership, a Maryland-based fund reported 163,000 shares. Swiss Comml Bank holds 67,252 shares. 48,539 were reported by Asset One Ltd. Voya Inv Management Ltd Com owns 0% invested in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) for 18,258 shares. Kentucky-based Teachers Retirement System Of The State Of Kentucky has invested 0.03% in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). Jennison Assocs Llc holds 0.02% in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) or 338,509 shares. Wellington Management Llp invested 0.06% in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). California-based Capital Intll Sarl has invested 0.57% in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). Perigon Wealth Management Ltd reported 0% of its portfolio in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). Northern Trust Corp accumulated 0.01% or 472,019 shares.

Among 21 analysts covering Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), 14 have Buy rating, 1 Sell and 6 Hold. Therefore 67% are positive. Ultragenyx Pharmaceutical Inc had 61 analyst reports since July 27, 2015 according to SRatingsIntel. The stock of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) earned “Buy” rating by Canaccord Genuity on Friday, July 28. The company was initiated on Tuesday, December 1 by Stifel Nicolaus. The stock has “Buy” rating by Jefferies on Friday, October 23. As per Wednesday, February 21, the company rating was maintained by Stifel Nicolaus. As per Thursday, September 14, the company rating was upgraded by Wedbush. Robert W. Baird maintained Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) on Tuesday, August 22 with “Buy” rating. Cowen & Co maintained the shares of RARE in report on Monday, December 4 with “Buy” rating. Leerink Swann initiated Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) on Friday, February 19 with “Outperform” rating. The stock of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) earned “Neutral” rating by H.C. Wainwright on Wednesday, April 19. The rating was initiated by Bank of America with “Buy” on Tuesday, June 28.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Hazel Jackson

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:








Recent Posts